Management strategies for nephrotoxicity

Transplantation

Volumn 69, Issue 12 SUPPL., 2000, Pages

  Macdonald, Allan S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; RAPAMYCIN; TACROLIMUS;

CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EXPOSURE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0342656574     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006271-00008     Document Type: Conference Paper

References (36)

1. Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long term cyclosporine and short term cyclosporine followed by azathioprine and prednisolone and azathioprine and prednisolone without cyclosporine. N Eng J Med 1988; 318(23): 1499-507.
2. Zanker B, Schneeberger H, Hillebrand G, et al. Mycophenolate mofetil-based, cyclosporine free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 1998; 66(1): 44-49
3. Grinyó JM. Progress with cyclosporine-sparing regimens. Transplant Proc 1999; 31(suppl 8A): 11S-16S.
4. Groth CG, Backman L, Morales J-M, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67(7): 1036-1042.
5. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68(1): 55-62.
6. Filler G, Mai I, Filler S, Ehrich JH. Abbreviated cyclosporine AUCs on Neoral - the search continues! Pediatr Nephrol 1999; 13(2): 98-102.
7. Sedrani R, Cottens, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998; 30: 2192-2194.
8. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, for the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63(7): 977-983.
9. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;344: 423-428.
10. Pichlmayr R, Winkler M, Neuhaus P, et al. Three-year follow-up of the European multicenter tacrolimus (FK506) liver study. Transplant Proc 1997; 29: 2499-2502.
11. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115.
12. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. Transplantation 1998; 66(4): 493-499.
13. Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Four-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 1999; 31(suppl 7A): 27S-28S.
14. Mayer AD, Dmitrewski J, Squifflet J-P, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation Q1997; 64(3): 436-443.
15. Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65(3): 446-449.
16. Furth S, Neu A, Colombani P, et al. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 1996; 10: 64-66.
17. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59(5): 655-661.
18. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61(7): 1029-1037.
19. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345(8961): 1321-1325.
20. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60(3): 225-232.
21. Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone verus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients. Transplantation 1998; 66(10): 1395-1398.
22. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67(3): 411-415.
23. Vincenti F, Grinyó J, Ramos E, et al. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc 1999; 31: 1246-1248.
24. Hueso M, Bover J, Seron D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 6(12): 1727-1731.
25. Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998; 31(5): 345-351.
26. Johnson EM, Zimmerman J, Duderstadt K, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996; 28(2): 987.
27. Napoli KL, Kahan BD. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem 1996; 42(12): 1943-1948.
28. Stepkowski SM, Kahan BD. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc 1991; 23(6): 3262-3264.
29. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolate reduces arterial internal thickening produced by mechanical injury and allows cyclosporine replacement. Transplantation 1995; 56: 655-666.
30. Sacks SH. Rapamycin on trial. Nephrol Dial Transplant 1999; 14: 2087-2089.
31. Kahan BD, for the Rapamune® U.S. Study Group. Sirolimus (Rapamune®, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial. Lancet 2000; in review.
32. MacDonald AS, The Rapamune® Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2000; in review.
33. Hausen B, Boeke K, Berry GJ, et al. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation 1999; 67(7): 956-62
34. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanism of suppression of murine T-cell activation by the related macrolides FK506 and rapamycin. J Immunol 1990; 144: 251-258.
35. Morris RE, Meiser BM, Wu J, et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506 and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23: 5-21.
36. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64(12): 1853-1856.